Serum anti-Spike immunoglobulin G levels in random blood donors in Italy: High-titre convalescent plasma is easier than ever to procure.
Vox Sang
; 118(9): 794-797, 2023 Sep.
Article
en En
| MEDLINE
| ID: mdl-37489640
ABSTRACT
BACKGROUND AND OBJECTIVES:
COVID-19 convalescent plasma (CCP) has retained potency and clinical efficacy against SARS-CoV-2 and is currently of utmost value for seronegative immunocompromised patients. Since most of the effect is due to the vaccine boost of infection-elicited antibodies, there is a theoretical concern that the frequency of suitable donors is declining. MATERIALS ANDMETHODS:
In this single-institution serosurvey, we screened 599 consecutive donors attending our area in two different seasons (300 in November 2022 and 299 in February 2023) using the Abbott Alinity® anti-Spike immunoglobulin G assay.RESULTS:
More than 80% of random donors qualify according to the FDA criteria for high-titre CCP (>4350 AU/mL), with a stable trend.CONCLUSION:
Despite reduced anti-Spike vaccine boost deployment in the general population, we have shown here that high-titre CCP units are easier than ever to procure. This finding also has implications for the derivation of standard immunoglobulins, which are finally approaching the potency of hyperimmune serum and could soon represent an alternative to CCP.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Vacunas contra el Cáncer
/
COVID-19
Tipo de estudio:
Clinical_trials
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Vox Sang
Año:
2023
Tipo del documento:
Article
País de afiliación:
Italia